TABLE 5.
Neoadjuvant chemoimmunotherapy and chemoimmunoradiotherapy
| Author | Reference | Trial name /trial number | Phase | Number of patients | Type of histology | Immune checkpoint inhibitor | Chemotherapeutic agent (+radiation dose) | ORR | pCR | MPR | R0 | AE grade III≦ | Mortality |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chemoimmunotherapy | |||||||||||||
| Zhang | 52 | ESONICT‐1 | II | 30 | ESCC | Sintilimab | Nab‐paclitaxel and cisplatin | 67% | 22% | 52% | 100% | 3% | 30 Day, 0% |
| Duan | 53 | SIN‐ICE | II | 23 | ESCC | Sintilimab | Docetaxel, nab‐paclitaxel and nedaplatin | 35% | 53% | 94% | 30% | 90 Day, 0% | |
| Yang, P | 54 | ChiCTR2100051903 | II | 16 | ESCC | Camrelizumab | Paclitaxel and carboplatin | 81% | 31% | 94% | 90 Day, 0% | ||
| Yang, G | 55 | retrospective | 12 | ESCC | Camrelizumab | Nab‐paclitaxel and S1 | 58% | 33% | 42% | 100% | 0% | 0% | |
| 56 | NCT03985670 | II | 30 | ESCC | Toripalimab | Paclitaxel and cisplatin | 67% | 21% (max.36%) | 100% | 3% | 30 Day, 4% | ||
| Shen | 57 | II | 28 | ESCC | Nivolumab, pembrolizumab and camrelizumab | Nab‐paclitaxel and carboplatin | 86% | 33% | 96% | 7% | Hospital, 0% | ||
| Chemoimmunoradiotherapy | |||||||||||||
| Li | 59 | PALACE‐1 | I | 20 | ESCC | Pembrolizumab | Paclitaxel and carboplatin (+41.4 Gy) | 56% | 89% | 94% | 65% | 90 Day, 0% | |
Abbreviations: AE, adverse event; ESCC, esophageal squamous cell carcinoma; MPR, major pathological response; ORR, objective response rate; pCR, pathological complete response; R0, no residual tumor.